Please use this identifier to cite or link to this item:
Title: Implication of VHL, ERK5, and HIF-1alpha in clear cell renal cell carcinoma: Molecular basis
Author: Serrano-Oviedo, Leticia
Giménez-Bachs, José Miguel
Nam-Cha, Syongh Y.
Cimas, Francisco J.
García-Cano, Jesús
Sánchez-Prieto, Ricardo
Salinas-Sánchez, Antonio S.
Keywords: Proteïnes
Biologia molecular
Marcadors tumorals
Càncer de ronyó
Molecular biology
Tumor markers
Renal cancer
Issue Date: 8-Nov-2016
Publisher: Elsevier Inc.
Abstract: Objectives: To determine the expression status of several proteins related to VHL gene function and its relationship with common clinicopathological parameters. Material and methods: Observational, analytical, cross-sectional study with 50 patients diagnosed with clear cell renal cell carcinoma. The study analyzed VHL mutations and hypermethylation as well as protein expression of VHL, CA-IX, HIF-1alpha, VEGF, ERK1/2, and ERK5, relating them to clinical variables. A bivariate and multivariate descriptive logistical regression analysis was performed, using the presence of metastasis at diagnosis as dependent variable. Results: The study identified 13 (26%) VHL mutations related to nuclear grade (P = 0.036). VHL hypermethylation was found in 20% of cases. VHL expression was associated with the presence of mutations (P = 0.013), and the absence of expression was associated with nuclear grade and the presence of metastasis (P<0.05). HIF-1alpha was negative in only 5 cases. Vascular endothelial growth factor (VEGF) was positive in 31 of 47 cases and was associated with Fuhrman nuclear grade, presence of metastasis, and stage (P<0.05). ERK5 expression was increased in 58% of cases and associated with the presence of metastasis and more advanced stages (P<0.05). In the logistic regression analysis, the only variable remaining in the model was VEGF expression (P = 0.014). Conclusions: VEGF has prognostic value in clear cell renal cell carcinoma, and ERK5 may be a new prognostic marker in this type of tumor owing to its relationship with metastasis and more advanced stages.
Note: Versió postprint del document publicat a:
It is part of: Urologic Oncology-Seminars and Original Investigations, 2017, vol. 35, num. 3, p. 114.e15-114.e22
Related resource:
ISSN: 1078-1439
Appears in Collections:Articles publicats en revistes (Ciències Fisiològiques)

Files in This Item:
File Description SizeFormat 
670347.pdf670.71 kBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons